参考资料 [1] Q. Ren, et al., (2023). Hsk7653, a novel biweekly DPP-4 inhibitor, versus daily linagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes. https://cattendee.abstractsonline.com/meeting/10899/Session/166 免责声明:药明康德内容团队专注介绍全球生物医药...
所以你如果要用GLP-1和GIP,那么你必须频繁注射才有效,这样比较麻烦,于是科学家想到了一个办法,抑制DPP-4的作用。于是就有了这一类新的降糖药物,DPP-4抑制剂(DPP-4 inhibitor)。 目前已经上市的药物有: 西格列汀(Sitagliptin),商品名:捷诺维(Januvia),规格100mg/片,1片,每天一次口服; 沙格列汀 (Saxagliptin),...
A DPP-4 inhibitor containing, as an active ingredient, a peptide represented by formula (1): Xe-Pro/Ala/Hyp-Xa-Xb-Xc-Xd (wherein Xe represents an amino acid residue having an isoelectric point of 5.9-6.3; Pro/Ala/Hyp represents Pro, Ala or Hyp; Xa represents an amino acid residue ...
5.LINONG JI, et al. 55-OR HSK7653, a Novel Ultralong-Acting DPP-4 Inhibitor, as Monotherapy in Patients with Type 2 Diabetes—A Randomized, Double-Blind, Placebo-Controlled Phase III Trial. ADA’s 83rd Scientific Sessions, 2023. 6.Q Ren, L Ji, L Li, et al. 642 - Hsk7653, a n...
17. Parmee, E.R., Sinharoy,R., Xu, F., Givand, J.C. and Rosen, L.A.(2012)Discovery and Development Of The DDP-4 Inhibitor Januvia(Sita-Gliptin), in Case Studies in Modern Drug Discovery and Development(eds X. Huang and...
所以你如果要用GLP-1和GIP,那么你必须频繁注射才有效,这样比较麻烦,于是科学家想到了一个办法,抑制DPP-4的作用。于是就有了这一类新的降糖药物,DPP-4抑制剂(DPP-4 inhibitor)。 目前已经上市的药物有: 西格列汀(Sitagliptin),商品名:捷诺维(Januvia),规格100mg/片,1片,每天一次口服;...
英文名称:dipeptidyl peptidases inhibitor 产品规格:1mL(10mM)|5mg|10mg|50mg Talabostat mesylate是一种可,特异性的dipeptidyl peptidases抑制剂,能够抑制DPP4的活性,IC50值为1nM。 注:本品仅可用于科研实验,严禁用于临床医疗及其他用途! CAS号:150080-09-4 ...
10. LINONG JI, FANG BIAN, TIANRONG PAN, et al. 55-OR HSK7653, a Novel Ultralong-Acting DPP-4 Inhibitor, as Monotherapy in Patients with Type 2 Diabetes—A Randomized, Double-Blind, Placebo-Controlled Phase III T...
[2]Dianna J Magliano(Co-chair),et al.IDF Diabetes Atlas.2021.[3]Linong Ji,et al.HSK7653, a Novel Ultralong-Acting DPP-4 Inhibitor, as Monotherapy in Patients With Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled Phase III Trial.2023ADA. ...